Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2014

01.04.2014 | Preclinical study

Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers

verfasst von: Weiwei Shi, Balint Balazs, Balazs Györffy, Tingting Jiang, W. Fraser Symmans, Christos Hatzis, Lajos Pusztai

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The goal of this analysis was to develop a computational tool that integrates the totality of gene expression, DNA copy number, and sequence abnormalities in individual cancers in the framework of biological processes. We used the hierarchical structure of the gene ontology (GO) database to create a reference network and projected mRNA expression, DNA copy number and mutation anomalies detected in single samples into this space. We applied our method to 59 breast cancers where all three types of molecular data were available. Each cancer had a large number of disturbed biological processes. Locomotion, multicellular organismal process, and signal transduction pathways were the most commonly affected GO terms, but the individual molecular events were different from case-to-case. Estrogen receptor-positive and -negative cancers had different repertoire of anomalies. We tested the functional impact of 27 mRNAs that had overexpression in cancer with variable frequency (<2–42 %) using an siRNA screen. Each of these genes inhibited cell growth in at least some of 18 breast cancer cell lines. We developed a free, on-line software tool (http://​netgoplot.​org) to display the complex genomic abnormalities in individual cancers in the biological framework of the GO biological processes. Each cancer harbored a variable number of pathway anomalies and the individual molecular events that caused an anomaly varied from case-to-case. Our in vitro experiments indicate that rare case-specific molecular abnormalities can play a functional role and driver events may vary from case-to-case depending on the constellation of other molecular anomalies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cao Y, DePinho RA, Ernst M, Vousden K (2011) Cancer research: past, present and future. Nat Rev Cancer 11:749–754PubMedCrossRef Cao Y, DePinho RA, Ernst M, Vousden K (2011) Cancer research: past, present and future. Nat Rev Cancer 11:749–754PubMedCrossRef
3.
Zurück zum Zitat Thomas RK et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef Thomas RK et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef
6.
Zurück zum Zitat Vaske CJ et al (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26:237–245CrossRef Vaske CJ et al (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26:237–245CrossRef
7.
Zurück zum Zitat Kamada T, Kawai S (1989) An algorithm for drawing general undirected graphs. Inf Process Lett (Elsevier) 31:7–15CrossRef Kamada T, Kawai S (1989) An algorithm for drawing general undirected graphs. Inf Process Lett (Elsevier) 31:7–15CrossRef
8.
Zurück zum Zitat Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef
10.
Zurück zum Zitat Iwamoto T, Bianchini G, Booser D, Qi Y et al (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272PubMedCrossRef Iwamoto T, Bianchini G, Booser D, Qi Y et al (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272PubMedCrossRef
11.
Zurück zum Zitat Andre F et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441–451PubMedCrossRef Andre F et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441–451PubMedCrossRef
12.
Zurück zum Zitat Nekrutenko A, Taylor J (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat Rev Genet 13:667–672 Nekrutenko A, Taylor J (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat Rev Genet 13:667–672
13.
Zurück zum Zitat Wang K, Li M, Hakonarson H (2010) Annovar: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164PubMedCentralPubMedCrossRef Wang K, Li M, Hakonarson H (2010) Annovar: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39(17):e118PubMedCentralPubMedCrossRef Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39(17):e118PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Ng PC, Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80PubMedCrossRef Ng PC, Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80PubMedCrossRef
17.
Zurück zum Zitat Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68:1675–1682PubMedCrossRef Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68:1675–1682PubMedCrossRef
18.
Zurück zum Zitat Torkamani A, Schork NJ (2007) Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics 23:2918–2925PubMedCrossRef Torkamani A, Schork NJ (2007) Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics 23:2918–2925PubMedCrossRef
Metadaten
Titel
Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers
verfasst von
Weiwei Shi
Balint Balazs
Balazs Györffy
Tingting Jiang
W. Fraser Symmans
Christos Hatzis
Lajos Pusztai
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2904-z

Weitere Artikel der Ausgabe 3/2014

Breast Cancer Research and Treatment 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.